Minerva Neurosciences, Inc.

NasdaqCM:NERV 주식 리포트

시가총액: US$203.1m

Minerva Neurosciences 향후 성장

Future 기준 점검 0/6

Minerva Neurosciences은 연간 수입과 매출이 각각 63.2%와 71.7% 증가할 것으로 예상되고 EPS는 연간 86.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

63.2%

이익 성장률

86.07%

EPS 성장률

Biotechs 이익 성장25.5%
매출 성장률71.7%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트18 May 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Oct 17

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences (NASDAQ:NERV), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a treatment targeted at schizophrenia patients. Without detailing reasons for the refusal, NERV said that the FDA had notified the company could request a Type A meeting to discuss the contents of the letter. Schizophrenia is a mental illness affecting an estimated 20M people globally.  "We are disappointed that the FDA has not accepted our NDA for roluperidone," Chief Executive Remy Luthringer remarked, adding, "the company intends to request a Type A meeting and looks forward to continued discussions with the FDA." NERV shares are currently on hold for trading.
Seeking Alpha • Aug 29

Minerva Neurosciences: Biotech On The Move

Summary NERV stock price has been on fire in recent days. Minerva Neurosciences' troubled roluperidone is just about its lone project candidate. Minerva's financial condition is fraught but adequate for the situation. Minerva Neurosciences (NERV) is a name I have not followed, nor even heard of, until its recent run. Its new price action makes for an interesting story. In this article I review its standing as an investment after its wild upswing. Minerva's shares traded with real urgency during the week of 08/22/2022 For Minerva the week preceding this 08/28/2022 writing was the week that was. After closing on Friday 08/19/2022 at $3.11, it hit a high of $5.19 on Monday 08/22/2022. Before market open on 08/22/2022, Minerva filed its long delayed, as hereafter discussed, NDA for its for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Also on Monday, Steve Cohen and Point72 filed a joint ownership 13G advising of acquisition of 470,000 shares, an 8.8% interest in Minerva. After resting a bit on Tuesday, digesting the news, by Wednesday 08/24/2022, Minerva's jets were firing again full steam, hitting a share price high of $8.58. Its volume Wednesday was exceptional leaping to >82 million shares. Thursday 08/25/2022 was another consolidation day. On Friday 08/26/2022 it hit a peak for the week at $10.89, closing out the week at $10.33 on a volume of >61 million shares. Its price for the week from the previous Friday trough of $3.11 to its following Friday peak of $10.89 reflected an increase of >250%. What has Minerva's longer term share movement looked like? The chart below draws out Minerva's share dynamics over recent years: NERV data by YCharts Minerva's steep 05/2020 downdraft (>-81%) following its negative data release for its phase 3 trial for roluperidone in treatment of negative symptoms in schizophrenia dwarfs its recent upswing. Minerva Neurosciences is a one trick pony with the one trick not yet fully mastered When trying to understand a new biotech name, I usually start by trying to run down its pipeline. For Minerva this endeavor was more difficult than typical. Its 2022 10-K atypically included zero help in this regard. I moved on to check out its website. Again atypically, it includes no entry for its "pipeline" as such. However when I searched for the word "pipeline" it took me to its "programs". There I found the following rather desolate entry which satisfied my need for a pipeline: minervaneurosciences.com As a preclinical program, one of many targeting Parkinson's Disease, I give Minerva's MIN-301 no real consideration. By my assessment MIN-301 is inconsequential in any current evaluation of Minerva. So Minerva is all about roluperidone (MIN-101) in treatment of negative symptoms of schizophrenia. Despite its rough road back with its phase 3 data release in 05/2020, Minerva is motoring ahead with this as fast as it can. Its progress has been halting at best as reflected by the following Seeking Alpha news items: 11/02/2020 Minerva schedules a Type C meeting with the FDA to advance its position of confidence in roluperidone and to discuss and define a forward path; 12/01/2020 Minerva and FDA at odds, with Minerva contending that the totality of the data demonstrates substantial evidence of effectiveness of the 64 mg dose, while FDA considers situation problematic for several reasons including inadequately powered phase 3 to show effectiveness; 05/11/2020 Minerva posts results from its Open-Label Extension [OLE] of its late stage roluperidone trial that it characterized as highly favorable in terms of longer term improvements in patients overall functioning "with few serious adverse events and no evidence of somnolence, extrapyramidal side effects or weight gain"; 09/30/2021 Minerva reported a positive bioequivalence study for roluperidone; 11/03/2021 FDA rebuffs Minerva request for a pre-NDA meeting for roluperidone, instead suggesting that a "Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy". It seems that Minerva finally got the point and went ahead with a Type C meeting. On 04/07/2022 it reported minutes from an 03/02/2022 Type C roluperidone meeting, purposed so that Minerva could obtain: ...the FDA’s agreement on the use of roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia in the subgroup of patients with moderate to severe negative symptoms and stable positive symptoms. On 04/13/2022 it set up a slide deck with its "Roluperidone Update Presentation". This was the material it used to illustrate its 04/03/2022 webcast with its Roluperidone Update; as I write on 08/28/2022 this webcast is still on Minerva's website. The summary slide at the close of this presentation addressed key issues raised by the FDA as follows: seekingalpha.com As I write on 08/28/2022, this is where the situation stands with Minerva's 08/22/2022 filing of its roluperidone NDA. Next stop for roluperidone is FDA decision on whether to approve its filing; we should hear on this within 60 days, likely late October. NERV will need to raise additional funds over its near to mid term Minerva seems to have given up on earnings conference calls, having run its last earnings call for Q3, 2021. This is unfortunate because such calls provide a nice add of color to straight earnings press releases and 10-K/Q's. But for whatever reason, current Minerva investors must make do with what's available. As for Minerva's Q2, 2022 earnings press release, it lists the essentials. Most notably it listed Minerva's bare bones liquidity position as of 06/30/2022 at ~$49.9 million. This compares to its cash, cash equivalents and restricted cash of ~$60.9 million as of 12/31/2021. Minerva's Q2, 2022 Statement of Operation below lists it most recent quarterly and semiannual operating expenses as follows: Minerva Q2, 2022 statement of operations excerpt (sec.gov)
Seeking Alpha • Aug 22

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Minerva Neurosciences (NASDAQ:NERV) filed an application to the U.S. Food and Drug Administration (FDA) seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. The company's new drug application (NDA) was backed by data from two late-stage studies (MIN-101C03 and MIN-101C07) in patients with moderate to severe negative symptoms and stable positive symptoms of schizophrenia. Minerva is seeking approval for the 64-mg dose of roluperidone. "While positive symptoms of schizophrenia are generally well managed with antipsychotics, negative symptoms are often the main burden of illness and can impact the patients’ quality of life as a result of disabilities caused by impaired vocational and social skills," said Executive Chairman and CEO Remy Luthringer. The company noted that there are currently no treatments approved for negative symptoms of schizophrenia in the U.S. NERV +7.89% to $3.35 premarket Aug. 22
분석 기사 • Jun 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Jan 26

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 02

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Mar 03

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. ( NASDAQ:NERV ) shareholders should be happy to see the share price up 15% in the last...
분석 기사 • Jan 27

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

A look at the shareholders of Minerva Neurosciences, Inc. ( NASDAQ:NERV ) can tell us which group is most powerful...
분석 기사 • Dec 23

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Nov 18

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences, Inc. (NASDAQ:NERV) shareholders should be happy to see the share price up 12% in the last...

이익 및 매출 성장 예측

NasdaqCM:NERV - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202813-52-63-573
12/31/2027N/A-50-55-413
12/31/2026N/A-156-47-333
3/31/2026N/A-415-15-15N/A
12/31/2025N/A-293-14-14N/A
9/30/2025N/A-14-14-14N/A
6/30/2025N/A11-16-16N/A
3/31/2025N/A6-18-18N/A
12/31/2024N/A1-20-20N/A
9/30/2024N/A-3-20-20N/A
6/30/2024N/A-34-21-21N/A
3/31/2024N/A-32-21-21N/A
12/31/2023N/A-30-15-15N/A
9/30/2023N/A-28-13-13N/A
6/30/2023N/A-27-18-18N/A
3/31/2023N/A-29-19-19N/A
12/31/2022N/A-32-25-25N/A
9/30/2022N/A-47-25-25N/A
6/30/2022N/A-49-24-24N/A
3/31/2022N/A-51-25-25N/A
12/31/2021N/A-50-25-25N/A
9/30/2021N/A-36-27-27N/A
6/30/2021N/A-35-28-28N/A
3/31/2021415-30-30N/A
12/31/2020412-34-34N/A
9/30/202041-21-41-41N/A
6/30/202041-27-40-40N/A
3/31/2020N/A-69-43-43N/A
12/31/2019N/A-72N/A-43N/A
9/30/2019N/A-55N/A-39N/A
6/30/2019N/A-54N/A-40N/A
3/31/2019N/A-54N/A-41N/A
12/31/2018N/A-50N/A-42N/A
9/30/2018N/A-37N/A-41N/A
6/30/2018N/A-36N/A-6N/A
3/31/2018N/A-33N/A-2N/A
12/31/2017N/A-32N/A3N/A
9/30/2017N/A-41N/A3N/A
6/30/2017N/A-38N/A-26N/A
3/31/2017N/A-34N/A-26N/A
12/31/2016N/A-31N/A-26N/A
9/30/2016N/A-30N/A-23N/A
6/30/2016N/A-28N/A-24N/A
3/31/2016N/A-29N/A-25N/A
12/31/2015N/A-27N/A-24N/A
9/30/2015N/A-26N/A-23N/A

애널리스트 향후 성장 전망

수입 대 저축률: NERV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: NERV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: NERV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: NERV 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: NERV 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: NERV의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 07:01
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Minerva Neurosciences, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Brian SkorneyBaird
Jason ButlerCitizens JMP Securities, LLC
Douglas TsaoH.C. Wainwright & Co.